Aeglea BioTherapeutics, Inc. logo

Aeglea BioTherapeutics, Inc.

Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”AGLE” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.aegleabio.com
Disease Focus
STOCK CODENASDAQ: AGLE
Address
901 S. MoPac Expressway, Barton Oaks Plaza One,Suite 250, TX 78746
Austin
United States
Email
Contact Number
+1 512-942-2935

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/aeglea-biotherapeutics” connections=”true” suffix=””]